BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

To Evaluate Effectiveness of Visanne in Improving Quality of Life in Asian Women With Endometriosis

Completed

Conditions: Endometriosis

Interventions: Drug: Dienogest (Visanne, BAY86-5258)

First Posted Date: 2015-04-24

Last Posted Date: 2019-09-25

Lead Sponsor: Bayer

Target Recruit Count: 895

Registration Number: NCT02425462

Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

Completed

Conditions: Macular Edema

Interventions: Drug: Aflibercept (Eylea, BAY86-5321)

First Posted Date: 2015-04-24

Last Posted Date: 2023-01-11

Lead Sponsor: Bayer

Target Recruit Count: 646

Registration Number: NCT02425501

Duration of Use of Highly Effective Reversible Contraception

Completed

Conditions: Pregnancy

Interventions: Drug: Mirena (Levonorgestrel IUS, BAY86-5028)
Drug: ParaGard
Drug: Implanon/Nexplanon

First Posted Date: 2015-04-13

Last Posted Date: 2017-03-16

Lead Sponsor: Bayer

Target Recruit Count: 13880

Registration Number: NCT02414919

Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Nifedipine (Adalat GITS, BAY1040)

First Posted Date: 2015-04-10

Last Posted Date: 2017-08-04

Lead Sponsor: Bayer

Target Recruit Count: 278

Registration Number: NCT02413515

Risk Minimisation Study for Diane-35 and Its Generics

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)

First Posted Date: 2015-04-07

Last Posted Date: 2017-04-05

Lead Sponsor: Bayer

Target Recruit Count: 759

Registration Number: NCT02410031

Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women

Phase 3

Completed

Conditions: Contraception

Interventions: Drug: Levonorgestrel (BAY98-7196)

First Posted Date: 2015-03-31

Last Posted Date: 2021-04-08

Lead Sponsor: Bayer

Target Recruit Count: 1471

Registration Number: NCT02403401

Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases

Completed

Conditions: Castration-Resistant Prostatic Cancer

Interventions: Drug: Radium-223 dichloride, (Xofigo, BAY88-8223)

First Posted Date: 2015-03-25

Last Posted Date: 2021-11-02

Lead Sponsor: Bayer

Target Recruit Count: 363

Registration Number: NCT02398526

Regorafenib Phase I Study in Mainland Chinese Patients

Phase 1

Completed

Conditions: Oncology

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2015-03-25

Last Posted Date: 2016-08-01

Lead Sponsor: Bayer

Target Recruit Count: 18

Registration Number: NCT02398513

Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients

Phase 3

Completed

Conditions: Glaucoma, Neovascular

Interventions: Drug: Aflibercept (Eylea, BAY 86-5321)
Drug: Sham Injection

First Posted Date: 2015-03-24

Last Posted Date: 2017-09-15

Lead Sponsor: Bayer

Target Recruit Count: 54

Registration Number: NCT02396316

Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment

Completed

Conditions: Hemophilia A

Interventions: Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)

First Posted Date: 2015-03-24

Last Posted Date: 2019-03-27

Lead Sponsor: Bayer

Target Recruit Count: 272

Registration Number: NCT02396862

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy